2026 PBM Transparency Regulations

Pharmacy Benefit Managers (PBMs) play a crucial role in managing prescription drug benefits for health plans, employers, and government programs. Yet, their complex business practices have often raised concerns about transparency, pricing, and patient access to medications. The 2026 PBM transparency regulations aim to address these issues by requiring PBMs to disclose more detailed information about their operations, pricing, and rebates. This blog post explains what these new regulations mean, how they will impact stakeholders, and what to expect moving forward.

What Are the 2026 PBM Transparency Regulations?

The 2026 PBM transparency regulations are a set of federal rules designed to increase openness in how PBMs operate. These regulations require PBMs to provide clear, accessible information about:

• How they negotiate drug prices and rebates with manufacturers

• The fees and spread pricing they apply

• The financial arrangements with pharmacies and health plans

• The impact of their practices on drug costs and patient access

  
  

The goal is to reduce hidden costs and conflicts of interest that can drive up drug prices and limit patient choices.

Why Were These Regulations Introduced?

PBMs have long been criticized for their opaque business models. Many stakeholders, including patients, employers, and policymakers, have struggled to understand how PBMs influence drug prices. Key concerns include:

• Lack of clarity on rebates: PBMs often receive rebates from drug manufacturers but do not always pass savings to patients or health plans.

• Spread pricing: PBMs may charge health plans more than they reimburse pharmacies, keeping the difference without disclosure.

• Conflicts of interest: PBMs sometimes own pharmacies or have financial ties that could affect their decisions.

  
  

These issues contribute to rising drug costs and can reduce access to affordable medications. The 2026 regulations aim to make PBM operations more transparent to promote fair pricing and better patient outcomes.

Key Requirements of the 2026 Regulations

The regulations set specific disclosure and reporting requirements for PBMs. Some of the most important include:

Detailed Reporting on Rebates and Fees

PBMs must report the total rebates and fees they receive from drug manufacturers. This includes:

• The amount of rebates negotiated

• How much of those rebates are passed on to health plans or patients

• Any fees charged to pharmacies or health plans

  
  

This reporting will help stakeholders understand how rebates affect drug prices.

Disclosure of Spread Pricing Practices

PBMs must disclose if they use spread pricing, showing the difference between what they charge health plans and what they pay pharmacies. This transparency will allow health plans to evaluate whether spread pricing is increasing costs unnecessarily.

Transparency in Pharmacy Networks

PBMs must provide clear information about their pharmacy networks, including:

• Which pharmacies are included

• Any ownership interests PBMs have in pharmacies

• How pharmacies are reimbursed

  
  

This will help ensure patients have access to a broad and fair pharmacy network.

Patient-Level Cost Information

PBMs will be required to provide patient-level data on drug costs, including:

• The actual cost of drugs after rebates and discounts

• Out-of-pocket costs for patients

• Any restrictions or prior authorization requirements

  
  

This data will empower patients and providers to make informed decisions about medications.

How Will These Regulations Affect Different Stakeholders?

For Patients

Patients can expect more transparency around the true cost of their medications. With clearer information on out-of-pocket expenses and drug pricing, patients will be better equipped to:

• Compare drug options

• Understand why certain drugs require prior authorization

• Advocate for lower costs with their providers or insurers

  
  

Greater transparency may also encourage PBMs to reduce unnecessary restrictions that limit access.

For Health Plans and Employers

Health plans and employers who contract with PBMs will gain access to detailed reports on pricing, rebates, and fees. This will allow them to:

• Negotiate better contracts with PBMs

• Identify hidden costs or unfair pricing practices

• Design benefit plans that better control drug spending

  
  

More transparency will help these groups hold PBMs accountable and improve the value of prescription drug benefits.

For Pharmacies

Pharmacies will benefit from clearer reimbursement information and disclosure of PBM ownership interests. This can:

• Reduce unfair spread pricing practices

• Promote fair competition among pharmacies

• Improve relationships between PBMs and pharmacies

  
  

Pharmacies may also see changes in network participation rules that affect their business.

For Drug Manufacturers

Manufacturers will face increased scrutiny on rebate negotiations. They may need to adjust pricing strategies knowing that rebate amounts and their distribution will be more visible. This could lead to:

• More competitive pricing

• Changes in rebate structures

• Greater focus on value-based contracts

  
  

Examples of Transparency in Action

Some states and private organizations have already implemented transparency measures that provide insight into how the 2026 regulations might work in practice.

• Ohio’s PBM Transparency Law requires PBMs to report rebate amounts and fees to state regulators. This has helped uncover spread pricing practices and led to more competitive contracts.

• Employer coalitions have demanded detailed PBM reporting to better understand drug costs and negotiate lower prices.

• Health plans using transparent PBM contracts have reported savings by eliminating hidden fees and ensuring rebates benefit patients.

  
  

These examples show that transparency can lead to cost savings and improved trust among stakeholders.

Challenges and Considerations

While the 2026 PBM transparency regulations promise many benefits, some challenges remain:

• Data complexity: PBM pricing and rebate data can be complex and difficult to interpret without expertise.

• Compliance costs: PBMs may face increased administrative costs to meet reporting requirements, which could affect pricing.

• Enforcement: Effective enforcement will be necessary to ensure PBMs comply fully and honestly.

• Patient privacy: Providing patient-level data must balance transparency with protecting sensitive health information.

  
  

Stakeholders will need to work together to address these challenges and make the most of the new rules.

Preparing for the 2026 Regulations

Health plans, employers, pharmacies, and PBMs should start preparing now by:

• Reviewing current contracts and identifying transparency gaps

• Investing in data systems to collect and report required information

• Training staff on new compliance requirements

• Engaging with stakeholders to communicate changes and expectations

  
  

Early preparation will help smooth the transition and maximize the benefits of transparency.